Marina Raikhel, MD
Family Medicine · Lomita, CANPI 1073792446
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.2%. Reporting peaked in 2023 at $18,108 and has fallen 87.7% since, to $2,223 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $176.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$9K
- AbbVie$7K
- Chiesi USA, Inc.$5K
- Redhill Biopharma Inc.$3K
- AstraZeneca$3K
- Novo Nordisk AS$2K
- plus $13K from 33 others
Across 1,845 payments — averaging $3060.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$767K
- Novo Nordisk AS$736K
- Ironwood Pharmaceuticals, Inc$700K
- AbbVie$516K
- GSK$497K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$451K
- plus $2M from 23 others
What the payments were for
- Consulting fees$2,3406%
- Speaking & faculty fees$17,05040%
- Travel & lodging$10,40025%
- Food & beverage$12,44429%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 13 | $9,416 |
| AbbVie(2 entities) | 28 | $7,138 |
| Chiesi USA, Inc. | 5 | $4,850 |
| Redhill Biopharma Inc. | 4 | $3,004 |
| AstraZeneca | 33 | $2,697 |
| Novo Nordisk AS | 10 | $2,408 |
| Biohaven Pharmaceuticals, Inc. | 5 | $1,514 |
| Shionogi Inc | 3 | $1,461 |
| Amgen(2 entities) | 16 | $1,460 |
| GSK | 23 | $1,022 |
| Novo Nordisk | 25 | $946 |
| Regeneron | 1 | $900 |
| Novartis | 8 | $883 |
| Bayer | 19 | $802 |
| E.r. Squibb & Sons, L.L.C. | 2 | $381 |
| Esperion Therapeutics, Inc. | 3 | $348 |
| Sanofi-aventis U.S. LLC | 4 | $326 |
| Johnson & Johnson | 5 | $298 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $247 |
| Regeneron Healthcare Solutions, Inc. | 2 | $241 |
| BD | 2 | $240 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $239 |
| Lilly USA, LLC | 5 | $193 |
| Boehringer Ingelheim | 3 | $157 |
| Madrigal Pharmaceuticals | 1 | $134 |
| Halozyme Inc | 1 | $127 |
| Sanofi | 1 | $126 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $126 |
| Lundbeck LLC | 2 | $125 |
| Medtronic | 1 | $108 |
| Exeltis, USA Inc. | 1 | $108 |
| Merck | 1 | $99 |
| Idorsia Pharmaceuticals US Inc | 1 | $86 |
| Radius Health, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $23 |
| Vertiflex, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,319 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $43,134 |
| FarxigaDapagliflozin Propanediol | 30 | $35,651 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $18,836 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,027 |
| EliquisApixaban | 13 | $12,016 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,543 |
| Levothyroxine Sodium | 125 | $2,366 |
| Losartan Potassium | 151 | $2,036 |
| SynthroidLevothyroxine Sodium | 16 | $1,790 |
| Atorvastatin Calcium | 220 | $1,650 |
| Olmesartan Medoxomil | 50 | $1,200 |
| Famotidine | 69 | $820 |
| Gabapentin | 66 | $750 |
| Diclofenac Sodium | 13 | $719 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $2,697 | $47,67749 claims |
| Novo NordiskOzempic | $946 | $43,13436 claims |
| GSKTrelegy Ellipta | $1,022 | $18,83629 claims |
| PfizerEliquis | $17 | $12,01613 claims |
| AbbVieSynthroid | $7,138 | $1,79016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Lomita
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.